SCHEMBL7149084

SCHEMBL7149084

CCOC(=O)c1ccc(NC(=O)CN(C)C(=O)[C@@H]2C[C@H](S)CN2S(=O)(=O)c2cccc3cccnc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
TP53 P04637 2/20 0.52
MME P08473 1/20 0.48
ACE P12821 1/20 0.48
ECE1 P42892 1/20 0.48
ALDH1A1 P00352 3/20 0.46
GAA P10253 3/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MPI P34949 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.42
HCRTR1 O43613 1/20 0.42
HTT P42858 2/20 0.42
MAPK1 P28482 1/20 0.42
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7139216 1.00 POLB (0.52) POLBTP53MMEACEECE1
SCHEMBL7142499 0.90 GAA (0.49) POLBTP53MMEACEECE1
SCHEMBL7150611 0.90 GAA (0.49) POLBTP53MMEACEECE1
SCHEMBL7149078 0.87 TP53 (0.54) POLBTP53ALDH1A1GAAMAPT
SCHEMBL7150544 0.83 ALDH1A1 (0.47) POLBTP53MMEACEECE1
SCHEMBL7145372 0.83 MME (0.46) POLBTP53MMEACEECE1
SCHEMBL7145369 0.83 MME (0.46) POLBTP53MMEACEECE1
SCHEMBL7143279 0.82 MME (0.70) TP53MMEACEECE1ALDH1A1
SCHEMBL7145879 0.82 MME (0.70) TP53MMEACEECE1ALDH1A1
SCHEMBL7135136 0.82 MME (0.70) TP53MMEACEECE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP POLB 1465/4885TP53 1366/4885MME 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.